About Erbi Bio
Erbi Bio is a Healthcare company based in Stoneham (United States) founded in 2016, and was acquired by Merck in December 2022. Microbioreactors for research purposes are manufactured by Erbi Bio. Erbi Bio has raised $7.8 million across 2 funding rounds from investors including Merck, Jaguar Health and Michael Chambers. Its chief executive, as recorded, is Michael Chiu. The company was acqui-hired. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Bioreactors. Its competitors include PBS Biotech and Ark Biotech; 2 of its 2 listed competitors have raised funding.
Company details
Erbi Bio was established in 2016 in Stoneham, United States, within the biotechnology sector. Microbioreactors are produced for research applications, supporting scientific experimentation in controlled environments. Operations are centered on manufacturing these devices, with distribution handled through the companys domain, erbi-bio.com. Leadership is provided by CEO Michael Chiu, overseeing activities in the research tools industry.
- Headquarters Stoneham, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website erbi-bio.com/en
- Social LinkedIn X
- Acquired by Merck (Dec 2022)
Funding Insights of Erbi Bio
Erbi Bio has successfully raised a total of $7.8M across 2 strategic funding rounds. The most recent funding activity was a Angel Round of $4 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.8M
- Total Rounds 2
- Last Round Angel Round — $4M
- First Round $3.8M
(Oct 2020)
- Investors Count 3
All 2 funding rounds of Erbi Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $4M | Angel Round | – | Michael Chambers, Martin Madaus | – |
| Oct 2020 | $3.8M | Series A | – | Jaguar Health | – |
4 investors in total: 2 institutional and 2 angel.
Investors in Erbi Bio
Erbi Bio has secured backing from 4 investors, including angel and institutional investors. Prominent investors backing the company include Merck, Jaguar Health and Michael Chambers.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Novel gastrointestinal products for humans and animals are developed sustainably. | 2013 | jaguar.health | San Francisco, United States | |
Merck is engaged in science and technology solutions globally. | 1668 | merckgroup.com | Darmstadt, Germany | |
MC Michael Chambers | Angel investor focusing on Indian startups, tech enthusiast | unknown_5f6837f6790544e2b | ||
MM Martin Madaus | Angel investor, ex-CEO of Millipore, focused on biotech and healthcare innovation. | unknown_d5604702fda744a19 |
Investor details for Erbi Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Erbi Bio
100 people are tracked at Erbi Bio (26 in leadership, 74 in team).
| Name | Role | Group |
|---|---|---|
Michael Chiu | CEO | Leadership |
Michal Daniely | Director, Research & Development | Leadership |
Jean-Charles Wirth | Head of Applied Solutions | Leadership |
David Hutchinson | General Counsel & Head of Legal Business Partners | Leadership |
Melissa Stoneman | Director, Global Marketing Communications | Leadership |
Karen Madden | Chief Technology Officer | Leadership |
Paul Ross | Director Of R&d And Technology Development | Leadership |
Matthias Heinzel | CEO | Leadership |
Shaf Yousaf | Chief Marketing Officer | Leadership |
Kasia Gralak McIpd | HR Business Partner | Leadership |
James Wareham | Vice President -global Sales, Inventory & Operational Planning | Leadership |
Bart Kerkman | Chief Information Officer | Leadership |
Tim M. Jaeger | EVP & Chief Strategy & Transformation Officer | Leadership |
Nelda Bonini | Head of Human Resources for Life Science | Leadership |
Gilles Fellous | Senior Director, IT Global Applications | Leadership |
Mark Robillard | VP - R&d | Leadership |
Steve Cecil | Director Strategic Business Development - Analytical | Leadership |
Cheryl Stipsits | Environmental, Health & Safety Director - St. Louis Operations | Leadership |
George Bleazard | Corporate Director - Ehs, Security, Transportation Compliance And Product Safety | Leadership |
Tish Creasey | Vice President, Operations & Marketing | Leadership |
80 more people are available in the full profile.
Complete people profiles for Erbi Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Erbi Bio
4 dated milestones of Erbi Bio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Erbi Bio is founded.
- Funding First funding round of $3.8M.
- Funding Latest funding round, Angel Round, of $4.0M.
- Exit Acquired by Merck.
Competitors of Erbi Bio
Erbi Bio has 2 listed competitors in our database, 2 of them funded. They include PBS Biotech and Ark Biotech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pbsbiotech.com | 2006 | Camarillo, United States | $70.21M | Developer of single-use bioreactors for the production of vaccines, therapeutic proteins, and cell therapies | ||
| ark-biotech.com | 2021 | Boston, United States | $10.68M | Bioreactors and systems for cultivated meat production are developed. |
Detailed competitors of Erbi Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Erbi Bio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Erbi Bio
Complete news archive for Erbi Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Erbi Bio
Erbi Bio was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Erbi Bio is headquartered in Stoneham, United States. It is registered at Stoneham, Massachusetts, United States.
Michael Chiu is the CEO of Erbi Bio, as recorded in our data.
Erbi Bio is a funded company, having raised a total of $7.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.8M, raised on Oct 2020.
Erbi Bio was established in 2016 in Stoneham, United States, within the biotechnology sector. Microbioreactors are produced for research applications, supporting scientific experimentation in controlled environments. Operations are centered on manufacturing these devices, with distribution handled through the companys domain, erbi-bio.com. Leadership is provided by CEO Michael Chiu, overseeing activities in the research tools industry.
Erbi Bio's top competitors include PBS Biotech and Ark Biotech.
Erbi Bio has 4 investors. Key investors include Merck, Jaguar Health, Michael Chambers, and Martin Madaus.
Yes. Erbi Bio was acquired by Merck in December 2022.